|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
An overview of the randomised trials. Lancet. 365:1687–1717. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaufmann M, Hortobagyi GN, Goldhirsch A,
Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R,
Jonat W, et al: Recommendations from an international expert panel
on the use of neoadjuvant (primary) systemic treatment of operable
breast cancer: An update. J Clin Oncol. 24:1940–1949. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Printz C: I-SPY 2 may change how clinical
trials are conducted: Researchers aim to accelerate approvals of
cancer drugs. Cancer. 119:1925–1927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Denkert C, Loibl S, Noske A, Roller M,
Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar
|
|
8
|
Jochems C and Schlom J: Tumor-infiltrating
immune cells and prognosis: The potential link between conventional
cancer therapy and immunity. Exp Biol Med (Maywood). 236:567–579.
2011. View Article : Google Scholar
|
|
9
|
Mao Y, Qu Q, Zhang Y, Liu J, Chen X and
Shen K: The value of tumor infiltrating lymphocytes (TILs) for
predicting response to neoadjuvant chemotherapy in breast cancer: A
systematic review and meta-analysis. PLoS One. 9:e1151032014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qi Q, Liu Y, Cheng Y, Glanville J, Zhang
D, Lee JY, Olshen RA, Weyand CM, Boyd SD and Goronzy JJ: Diversity
and clonal selection in the human T-cell repertoire. Proc Natl Acad
Sci USA. 111:13139–13144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scaviner D and Lefranc MP: The human T
cell receptor alpha variable (TRAV) genes. Exp Clin Immunogenet.
17:83–96. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Folch G and Lefranc MP: The human T cell
receptor beta variable (TRBV) genes. Exp Clin Immunogenet.
17:42–54. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clambey ET, Davenport B, Kappler JW,
Marrack P and Homann D: Molecules in medicine mini review: The αβ T
cell receptor. J Mol Med Berl. 92:735–741. 2014. View Article : Google Scholar
|
|
15
|
Fang H, Yamaguchi R, Liu X, Daigo Y, Yew
PY, Tanikawa C, Matsuda K, Imoto S, Miyano S and Nakamura Y:
Quantitative T cell repertoire analysis by deep cDNA sequencing of
T cell receptor α and β chains using next-generation sequencing
(NGS). Oncoimmunology. 3:e9684672015. View Article : Google Scholar
|
|
16
|
Liu X, Venkataraman G, Lin J, Kiyotani K,
Smith S, Montoya M, Nakamura Y and Kline J: Highly clonal
regulatory T-cell population in follicular lymphoma - inverse
correlation with the diversity of CD8(+) T cells. Oncoimmunology.
4:e10027282015. View Article : Google Scholar
|
|
17
|
Jang M, Yew PY, Hasegawa K, Ikeda Y,
Fujiwara K, Fleming GF, Nakamura Y and Park JH: Characterization of
T cell repertoire of blood, tumor, and ascites in ovarian cancer
patients using next generation sequencing. Oncoimmunology.
4:e10305612015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yew PY, Alachkar H, Yamaguchi R, Kiyotani
K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, et al:
Quantitative characterization of T-cell repertoire in allogeneic
hematopoietic stem cell transplant recipients. Bone Marrow
Transplant. 50:1227–1234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamura K, Hazama S, Yamaguchi R, Imoto S,
Takenouchi H, Inoue Y, et al: Characterization of T cell repertoire
in tumor tissues and blood in advanced colorectal cancers through
deep T cell receptor sequencing. Oncol Lett. (In press).
|
|
20
|
Choudhury NJ, Kiyotani K, Yap KL,
Campanile A, Antic T, Yew PY, Steinberg G, Park JH, Nakamura Y and
O'Donnell PH: Low T cell receptor diversity, high somatic mutation
burden, and high neoantigen load as predictors of clinical outcome
in muscle-invasive bladder cancer. Eur Urol Focus. Oct 8–2015.
View Article : Google Scholar
|
|
21
|
Ellingson MS, Hart SN, Kalari KR, Suman V,
Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X,
et al: Exome sequencing reveals frequent deleterious germline
variants in cancer susceptibility genes in women with invasive
breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer
Res Treat. 153:435–443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giudicelli V, Chaume D and Lefranc MP:
IMGT/GENE-DB: A comprehensive database for human and mouse
immunoglobulin and T cell receptor genes. Nucleic Acids Res.
33:D256–D261. 2005. View Article : Google Scholar :
|
|
23
|
Langmead B and Salzberg SL: Fast
gapped-read alignment with Bowtie 2. Nat Methods. 9:357–359. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bolotin DA, Shugay M, Mamedov IZ,
Putintseva EV, Turchaninova MA, Zvyagin IV, Britanova OV and
Chudakov DM: MiTCR: Software for T-cell receptor sequencing data
analysis. Nat Methods. 10:813–814. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Turley SJ, Cremasco V and Astarita JL:
Immunological hallmarks of stromal cells in the tumour
microenvironment. Nat Rev Immunol. 15:669–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park JH: Immune microenvironment to
predict response of cancer chemotherapy and radiotherapy.
Immunopharmacogenomics. Nakamura Y: Springer; Tokyo: pp. 143–155.
2015, View Article : Google Scholar
|
|
27
|
Gebremeskel S and Johnston B: Concepts and
mechanisms underlying chemotherapy induced immunogenic cell death:
Impact on clinical studies and considerations for combined
therapies. Oncotarget. 6:41600–41619. 2015.PubMed/NCBI
|
|
28
|
Hong M, Puaux A-L, Huang C, Loumagne L,
Tow C, Mackay C, Kato M, Prévost-Blondel A, Avril MF, Nardin A, et
al: Chemotherapy induces intratumoral expression of chemokines in
cutaneous melanoma, favoring T-cell infiltration and tumor control.
Cancer Res. 71:6997–7009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oda N, Shimazu K, Naoi Y, Morimoto K,
Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ and Noguchi S:
Intratumoral regulatory T cells as an independent predictive factor
for pathological complete response to neoadjuvant paclitaxel
followed by 5-FU/epirubicin/cyclophosphamide in breast cancer
patients. Breast Cancer Res Treat. 136:107–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsushita N, Pilon-Thomas SA, Martin LM
and Riker AI: Comparative methodologies of regulatory T cell
depletion in a murine melanoma model. J Immunol Methods.
333:167–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ladoire S, Arnould L, Apetoh L, Coudert B,
Martin F, Chauffert B, Fumoleau P and Ghiringhelli F: Pathologic
complete response to neoadjuvant chemotherapy of breast carcinoma
is associated with the disappearance of tumor-infiltrating
foxp3+ regulatory T cells. Clin Cancer Res.
14:2413–2420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han A, Glanville J, Hansmann L and Davis
MM: Linking T-cell receptor sequence to functional phenotype at the
single-cell level. Nat Biotechnol. 32:684–692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakamura Y: Challenges and future
directions of immunopharmacogenomics. Immunopharmacogenomics.
Nakamura Y: Springer; Tokyo: pp. 159–162. 2015, View Article : Google Scholar
|
|
34
|
Rapoport AP, Stadtmauer EA, Binder-Scholl
GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B,
Finklestein J, et al: NY-ESO-1-specific TCR-engineered T cells
mediate sustained antigen-specific antitumor effects in myeloma.
Nat Med. 21:914–921. 2015. View Article : Google Scholar : PubMed/NCBI
|
